source
- Eli Lilly to seek approval next year for retatrutide after strong Phase 3 obesity resultsEli Lilly announced that its experimental obesity drug retatrutide will be submitted to regulators for approval early next year. The decision follows recent Phase 3 trial data that showed the drug…
- GSK receives FDA approval for ROS1 inhibitor Jideytro, marking its first lung cancer drugGSK's FDA approval of Jideytro, a ROS1 inhibitor for advanced non-small cell lung cancer patients with ROS1 gene fusions who have already received ROS1-directed therapy, was announced on Wednesday.…